Among the treated patients with    lonafarnib, an obscure little farnesyl transferase inhibitor , just four died over the two years of study, compared to 17 deaths in the untreated group. These results are unheard of in Hutchinson-Gilford Progeria, a genetic condition characterized by premature aging . Results this strong are rarely seen in most diseases, actually.